ARS Pharmaceuticals Secures Patent Validity for neffy® Spray
ARS Pharmaceuticals Achieves Key Patent Victory in Europe
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company based in San Diego, specializes in providing tools for at-risk individuals to effectively address allergic reactions that can culminate in anaphylaxis. Recently, the company received a positive ruling from the Opposition Division of the European Patent Office (EPO), which successfully upheld all claims of their patent EP 3678649. This patent is significant as it pertains to nasal spray epinephrine formulations that have been validated across over 30 countries in Europe, particularly utilizing alkyl-glycoside, like Intravail.
Strengthening the Patent Portfolio
ARS Pharma's global intellectual property assets related to the innovative product, neffy, offer robust coverage extending until at least 2039. This steadfastness in patent protection supports the company's competitive positioning in the market for emergency treatments against severe allergic reactions.
Similar Success in the United States
Earlier in the year, ARS Pharma successfully defended its patent rights in the United States. The United States Patent and Trademark Office (USPTO) upheld critical claims of U.S. Patent No. 10,682,414, which covers the method of treating type I hypersensitivity reactions, including anaphylaxis, using an epinephrine aqueous nasal spray. This dual success across different jurisdictions underscores the extensive validity of ARS's patents.
CEO Commentary
Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma, expressed his optimism regarding these favorable outcomes. He affirmed that "the decisive and unanimous opinion of the EPO committee in rejecting all opposition arguments affirms the strength and validity of our extensive patent portfolio." Lowenthal's comments highlight the company's confidence in successfully handling future patent challenges, especially those pertaining to intranasal epinephrine formulations.
About neffy®
Introduced as a groundbreaking tool for emergency management, neffy serves as an epinephrine nasal spray specifically designed for the urgent treatment of anaphylactic reactions in both adults and children aged four and above, who weigh at least 33 pounds. This innovative method provides an alternative form of administration compared to traditional injectable options.
Usage Instructions and Safety Information
The indication for neffy emphasizes that users should carry two nasal sprays at all times, as anaphylactic reactions can be unpredictable. If symptoms persist or worsen following the initial dose, a second spray may be necessary. neffy is intended only for intranasal use, and it is crucial to seek immediate medical assistance for additional treatment following any allergic reaction.
The Importance of Combatting Anaphylaxis
Anaphylaxis represents a severe and rapidly progressing allergic reaction typically necessitating immediate treatment with epinephrine, the only FDA-approved solution for such emergencies. Unfortunately, the current roster of epinephrine auto-injectors often presents challenges that deter prompt administration. Patient apprehensions, including needle phobia, complex operating procedures, and issues related to device reliability have resulted in a large number of individuals not using their prescribed devices in critical situations.
The Need for Effective Solutions
In the United States alone, around 40 million individuals are at risk for type I allergic reactions, underscoring a significant market potential for effective treatments like neffy. However, many patients face hurdles in carrying and using traditional epinephrine auto-injectors, although in recent years, a growing number have been diagnosed with severe allergies leading to anaphylaxis.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals aims to transform the landscape of allergic reaction treatments through neffy, which has been approved in the EU under the trade name EURneffy. This nasal spray is instrumental for immediate intervention for anaphylactic responses due to various allergic stimuli, making it a vital tool for both patients and caregivers.
Contact Information for ARS Pharmaceuticals
For inquiries, please contact ARS Pharmaceuticals at 1-877-MY-NEFFY (877-696-3339) or reach out to their media contacts. For further details about their innovative offerings, visit ARS Pharmaceuticals' official website.
Frequently Asked Questions
What is neffy®?
neffy® is a nasal spray built for the emergency treatment of allergic reactions, including anaphylaxis, for individuals weighing at least 33 pounds.
What recent patent news has ARS Pharmaceuticals announced?
ARS Pharmaceuticals has successfully upheld a patent related to neffy® at the European Patent Office, affirming the reliability of their product.
Why is epinephrine important in treating allergies?
Epinephrine is crucial as it rapidly counteracts severe allergic reactions, which can be life-threatening if not treated promptly.
What distinguishes neffy® from traditional epinephrine injectors?
neffy® provides a needle-free method for epinephrine administration, addressing fears associated with needles and simplifying the treatment process.
How should neffy® be stored and used?
neffy® should be stored at room temperature and always carried in pairs to ensure immediate access during an allergic emergency.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
